Black Diamond Therapeutics, Inc.
HealthcareNASDAQ:BDTX · NASDAQ Global Select
-$0.07 today
Vol 2.31M · Avg 1.22M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
19.9%
avg -10.9%
ROIC
15.6%
avg -39.8%
ROA
15.6%
avg -35.5%
Analysis
ROE is currently the strongest return metric at 19.9% versus its period average of -10.9%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Mark A. Velleca | Chief Executive Officer, President & Chairman | $1.04M | — | 62 | $600,000.00 | 1.05% |
Sergey Yurasov | Chief Medical Officer | $760,748.00 | — | 57 | $250,000.00 | 0.44% |
Brent Hatzis-Schoch | Chief Operating Officer & General Counsel | $741,216.00 | — | 61 | $250,000.00 | 0.44% |
Elizabeth Buck | Co-Founder & Chief Scientific Officer | $340,473.00 | — | 51 | $250,000.00 | 0.44% |
Erika Jones | Principal Financial Officer, Principal Accounting Officer, SVP of Finance & Corporate Controller | — | — | 41 | $200,000.00 | 0.35% |
Melanie Morrison | Chief Development Officer | — | — | 51 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Abeona Therapeutics Inc.
NASDAQ:ABEO
$315.18M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Fennec Pharmaceuticals Inc.
NASDAQ:FENC
$257.22M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$245.42M
Inventiva S.A.
NASDAQ:IVA
$200.13M
Avalo Therapeutics, Inc.
NASDAQ:AVTX
$166.70M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$158.19M
Immuneering Corporation
NASDAQ:IMRX
$152.11M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$118.59M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
$85.08M
Who manages BDTX?
Black Diamond Therapeutics, Inc. (BDTX) lists 6 active executives. The top listed executive is Brent Hatzis-Schoch, Chief Operating Officer & General Counsel.
Are BDTX insiders buying or selling?
Recent insider activity shows net buying of $37.70M.
Explore More
Continue the stock analysis
Jump to another research area for this company.